UTD THERAP. (DEL.) DL-,01UU

UTD THERAP. (DEL.) DL-,01

317.4EURD
−23.9−7.00%
As of today at 14:31 GMT
EUR
No trades
See on Supercharts
Next report date
April 30
Report period
Q1 2025
EPS estimate
6.66 EUR
Revenue estimate
‪717.76 M‬ EUR
Market capitalization
‪15.18 B‬EUR
21.9EUR
‪892.24 M‬EUR
‪2.11 B‬EUR
‪43.70 M‬
Beta (1Y)
0.68
Employees (FY)
‪1.17 K‬
Change (1Y)
+183 +18.58%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About United Therapeutics Corporation


CEO
Martine A. Rothblatt
Headquarters
Silver Spring
Founded
1996
FIGI
BBG000BJF5L4
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Performance
‪35%‬
‪38%‬
‪41%‬
‪44%‬
‪47%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬
‪‪680.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬
‪‪680.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬
‪‪680.00 M‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Apr 30, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where UTH is featured.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange UTD THERAP. (DEL.) DL-,01 stocks are traded under the ticker UTH.
We've gathered analysts' opinions on UTD THERAP. (DEL.) DL-,01 future price: according to them, UTH price has a max estimate of 570.75 EUR and a min estimate of 312.01 EUR. Watch UTH chart and read a more detailed UTD THERAP. (DEL.) DL-,01 stock forecast: see what analysts think of UTD THERAP. (DEL.) DL-,01 and suggest that you do with its stocks.
UTH reached its all-time high on Nov 11, 2024 with the price of 381.2 EUR, and its all-time low was 9.5 EUR and was reached on Aug 9, 2001. View more price dynamics on UTH chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track UTD THERAP. (DEL.) DL-,01 financials in yearly and quarterly reports right on TradingView.
UTD THERAP. (DEL.) DL-,01 is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
UTH earnings for the last quarter are 5.98 EUR per share, whereas the estimation was 6.33 EUR resulting in a −5.60% surprise. The estimated earnings for the next quarter are 6.66 EUR per share. See more details about UTD THERAP. (DEL.) DL-,01 earnings.
UTD THERAP. (DEL.) DL-,01 revenue for the last quarter amounts to ‪710.86 M‬ EUR, despite the estimated figure of ‪715.66 M‬ EUR. In the next quarter, revenue is expected to reach ‪717.76 M‬ EUR.
UTH net income for the last quarter is ‪277.62 M‬ EUR, while the quarter before that showed ‪259.63 M‬ EUR of net income which accounts for 6.93% change. Track more UTD THERAP. (DEL.) DL-,01 financial stats to get the full picture.
No, UTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 26, 2025, the company has ‪1.17 K‬ employees. See our rating of the largest employees — is UTD THERAP. (DEL.) DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UTD THERAP. (DEL.) DL-,01 EBITDA is ‪1.21 B‬ EUR, and current EBITDA margin is 53.35%. See more stats in UTD THERAP. (DEL.) DL-,01 financial statements.
Like other stocks, UTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UTD THERAP. (DEL.) DL-,01 stock right from TradingView charts — choose your broker and connect to your account.